BMS-986517 / BMS - LARVOL DELTA

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=540 | Recruiting | Sponsor: Bristol-Myers Squibb | N=315 ➔ 540

Enrollment change • First-in-human • Monotherapy • Breast Cancer • Head and Neck Cancer • HER2 Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • HER-2

CA2540001: A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants with Advanced Solid Tumors (clinicaltrialsregister.eu) - P1/2 | N=29 | Recruiting | Sponsor: Bristol-Myers Squibb Services Unlimited Company | N=11 ➔ 29

Enrollment change • First-in-human • Monotherapy • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

CA2540001: A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants with Advanced Solid Tumors (clinicaltrialsregister.eu) - P1/2 | N=11 | Recruiting | Sponsor: Bristol-Myers Squibb Services Unlimited Company

First-in-human • Monotherapy • New P1/2 trial • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=315 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Monotherapy • Solid Tumor

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=315 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

Monotherapy • New P1/2 trial • Solid Tumor